CSDDD Omnibus Explained – Practical interpretation (Pharma) Scenerio -1

Case:

EU MAH → CMO (India) → API supplier (India)

Under Omnibus CSDDD:

Tier	Entity	Legal CSDDD Expectation	Practical Pharma Reality
Tier 0	EU MAH	✔ Fully in scope under the Corporate Sustainability Due Diligence Directive	Full QMS integration with ESG embedded into governance and oversight
Tier 1	CMO	✔ Direct due diligence required	Already audited under Good Manufacturing Practice + ESG overlay added
Tier 2	API supplier	⚠ Risk-triggered due diligence	Typically already qualified under GMP; ESG depth depends on risk profile
Tier 3	Raw materials	❌ Not routinely required (unless risk triggers)	Rarely visible or assessed unless critical or high-risk input

Key takeaway

The Omnibus proposal effectively says:

“Focus on direct suppliers, and only go deeper when risk justifies it.”

BUT in pharma:

go deeper than the law requires
So the real impact is:
- Formalising ESG within existing supplier qualification systems
- Not building entirely new layers

Strategic implication (non-obvious but important)

EU MAHs remain the regulatory anchor
Non-EU CMOs/APIs avoid direct legal scope
BUT:
- They become contractually bound
- And subject to expanded audit scope (ESG + GMP)

Bottom line

Under the Omnibus approach: